BOCA RATON, Fla., Jan. 17, 2012 /PRNewswire/ -- Vycor Medical, Inc. (OTCBB: VYCO) ("Vycor") today announced that its ViewSite Brain Access System ("VBAS") has received clearance from the State Food and Drug Administration ("SFDA") in the People's Republic of China ("PRC") to be imported and marketed in the PRC. This follows the issue of its patent in China for VBAS in 2011.
Kenneth Coviello, the Chief Executive of Vycor, commented: "We are delighted to have achieved this important milestone in Vycor's development. VBAS has received outstanding reviews from surgeons in the United States where it continues to gain traction with hospitals and neurosurgeons. We believe that the Chinese medical device market has tremendous potential for Vycor and are excited to begin working with healthcare professionals in China and look forward to the expansion of VBAS in the region."
Underlining the importance of this milestone, Vycor has received an opening order for the Chinese market with a value of $170,000, which it shipped prior to the end of December 2011.
For more information about how VBAS works, or to read testimonials, please visit www.vycormedical.com
About Vycor Medical, Inc.
With corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. (VYCO.BB) is a medical device company committed to making neurological brain, spinal and other surgical procedures safer and more effective. The company's flagship, Patent Pending ViewSite Surgical Access Systems represent an exciting new minimally invasive access and retraction system that holds the potential for speedier, safer and more economical brain, spinal and other surgeries and a quicker patient discharge. Vycor's innovative medical instruments are designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery, and add tangible value to the professional medical community. Vycor is ISO 13485:2003 compliant, has FDA 510(K) clearance for brain and spine surgeries, and CE Marking and HPB licensing in Canada.
Vycor Medical's subsidiary NovaVision, Inc. researches, develops and provides science-driven light-based neurostimulation therapy and other medical technologies that help restore sight to patients with neurological vision impairments. The company's proprietary, Visual Restoration Therapy (VRT) platform is clinically supported to improve lost vision resulting from stroke, brain cancer, traumatic brain injury ("TBI"), or other acquired brain injury, and has been cleared to be marketed in the US by the FDA. VRT can be prescribed by any ophthalmologist, optometrist, neurologist or physiatrist. NovaVision also provides a device that aids in the early identification of visual field deficits: the Head Mounted Perimeter (HMPTM) - a portable and ADA-compliant instrument to aid in the detection and measurement of visual field deficits even in bed-ridden patients.
For the latest information on the company, including media and other coverage, and to learn more, please go online at www.vycormedical.com or www.novavision.com.
Safe Harbor Statement
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Vycor Medical's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Vycor Medical's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Vycor Medical herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Vycor Medical disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
Karen Coviello, 561-558-2000, firstname.lastname@example.org
SOURCE Vycor Medical